Psoriasis Longitudinal Assessment and Registry (PSOLAR)
common.study.values.description
“Psoriasis Longitudinal Assessment and Registry (PSOLAR)”
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque psoriasis, and other all forms of psoriasis (such as plaque psoriasis and psoriatic arthritis occurring together). The registry study will track the behavior of the disease in response to other therapies, such as other biologic drugs. The registry will also evaluate clinical outcomes; disease characteristics, including physician reported assessment of psoriatic arthritis (PsA); quality of life, and potential risks for patients who may receive standard therapies for psoriasis.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Biological - Ustekinumab
Ustekinumab will be administered as prescribed by physician.
Biological - Biological therapies other than infliximab, ustekinumab and guselkumab
Biological therapies will be administered as prescribed by physician.
Drug - Conventional systemic agents
Conventional systemic agents will be administered as prescribed by physician.
Biological - Infliximab
Infliximab will be administered as prescribed by physician.
Biological - Guselkumab
Guselkumab will be administered as prescribed by physician.
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics
common.study.values.clinical-trial-id
NCT00508547
participant.views.study.view.id
PdR6qd
